Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls
Executive Summary
The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.
You may also be interested in...
Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval
The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.
Roche Seeks Speedy EU Review For Second Bispecific Antibody
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.
AstraZeneca’s Evusheld Wins EU Marketing Nod For Preventing COVID-19
The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.